Biological E. Limited Heparin Export Data — India (DGFT 2022–2026)

Name: Biological E. Limited Heparin Export Records India — #13 Exporter, 13 Shipments, $650.0K FOB USD (DGFT 2022–2026)
Creator: TransData Nexus
Published: 2026-05-01T00:00:00Z
License: https://transdatanexus.com/terms-and-conditions

Suresh Sormare

Heparin

India Pharmaceutical Trade Intelligence

$352.8M391 Suppliers137 CountriesHS 30049099

ExportsIndia → UNITED STATES42.1%India → SAUDI ARABIA12.3%

ImportsCHINA → India$508.4B BELGIUM → India$2.8B

#1 Supplier: GLAND PHARMA #1 Buyer: FRESENIUS KABI

Biological E. Limited — Heparin Exporter #13 | $650.0K Trade Value | TransData Nexus | TransData Nexus

Biological E. Limited — Heparin Exporter Profile

Indian Pharmaceutical Exporter · #13 for Heparin · $650.0K export value · DGFT Verified

Biological E. Limited is the #13 Indian exporter of Heparin with $650.0K in export value and 13 verified shipments. Biological E. Limited holds a 0.2% market share in Heparin exports across 2 countries. The company exports 5 pharmaceutical products worth $80.3M across 3 therapeutic categories.

Biological E. Limited — Heparin Export Profile: Buyers & Destinations

Biological E. Limited Heparin export treemap — buyers and destination countries | TransData Nexus

Where Does Biological E. Limited Export Heparin?

Country	Value	Shipments	Share
UNITED STATES	$572.1K	12	79.2%
CANADA	$150.0K	4	20.8%

Biological E. Limited exports Heparin to 2 countries. The largest destination is UNITED STATES accounting for 79.2% of Biological E. Limited's Heparin shipments. These destinations reflect Biological E. Limited's established distribution network and regulatory approvals in key markets.

Who Are the Top Buyers of Heparin from Biological E. Limited?

Buyer

What Heparin Formulations Does Biological E. Limited Export?

Product Description / Formulation	Value	Shipments
HEPARIN SODIUM INJECTION USP 5000 USP UNITS PER 0.5ML	$150.0K	3
HEPARIN SODIUM INJECTION USP 5 000 USP	$150.0K	3
51000335 - HEPARIN SODIUM INJECTION, USP	$100.0K	2
51000335 - HEPARIN SODIUM INJECTION USP	$50.0K	1
51000335 - HEPARIN SODIUM INJECTION,USP	$50.0K	1
51000787 - Heparin sodium injection USP,5000 USP Units/0.5mL BATCH-11E011AA, MFG. - NOV-2024 EXP. - OCT-2027	$50.0K	1
51000787 - Heparin sodium injection USP,5000 USP Units/0.5mL BATCH-11E013AA ,MFG. - DEC-2024 EXP. - NOV-2027	$50.0K	1
51000787 - Heparin sodium injection USP,5000 USP Units/0.5mL BATCH-11E014AA ,MFG. - DEC-2024 EXP. - NOV-2027	$50.0K	1
HEPARIN SODIUM INJECTION USP 5000 USP UNITS PER 0.5ML43200NOS2.31	$50.0K	1
51000334 - HEPARIN SODIUM INJECTION,USP	$22.1K	1

Biological E. Limited exports 11 distinct Heparin formulations including tablets, capsules, syrups, and combination drugs. The top formulation is HEPARIN SODIUM INJECTION USP 5000 USP UNITS PER 0.5ML with 3 shipments worth $150.0K.

How Does Biological E. Limited Compare to Nearest Heparin Exporters?

Exporters ranked immediately above and below #13 by export value

#	Supplier	Export Value	Shipments	Countries	Avg/Shipment
8	JODAS EXPOIM PRIVATE LIMITED	$1.1M	23	2	$50.0K
11	EUGIA PHARMA SPECIALITIES LIMITED	$700.0K	14	2	$50.0K
13	BIOLOGICAL E. LIMITED ★	$650.0K	13	2	$50.0K
15	U SQUARE LIFESCIENCE PRIVATE LIMITED	$400.0K	8	1	$50.0K
12	TC WORLD	$150.0K	3	1	$50.0K

Biological E. Limited ranks #13 among 391 Indian Heparin exporters. Average shipment value of $50.0K compared to the market average of $288.0K. The closest competitors by value are JODAS EXPOIM PRIVATE LIMITED and EUGIA PHARMA SPECIALITIES LIMITED.

Which Indian Ports Ship Heparin Exports?

Port	Shipments	% Share
HYDERABAD ICD	669	14.6%
SAHAR AIR CARGO ACC (INBOM4)	507	11.1%
HYDERABAD ICD (INSNF6)	486	10.6%
SAHAR AIR	441	9.6%
DELHI AIR CARGO ACC (INDEL4)	221	4.8%
NHAVA SHEVA SEA (INNSA1)	213	4.6%
Bombay Air	156	3.4%
HYDERABAD AIR	153	3.3%

Geopolitical & Trade Policy Impact on Biological E. Limited's Heparin Exports

The current geopolitical climate presents both challenges and opportunities for Indian pharmaceutical exporters like BE. The Israel-Iran conflict has disrupted Red Sea shipping routes, leading to increased freight charges and potential losses estimated between ₹2,500 crore and ₹5,000 crore for the Indian pharma industry in March 2026. (fortuneindia.com) These disruptions can elongate lead times and elevate cold-chain failure risks, particularly for temperature-sensitive products like vaccines. (pharmaceuticalcommerce.com)

Conversely, U.S.-China trade tensions have prompted the U.S. to seek alternative suppliers, potentially benefiting Indian exporters. However, the imposition of tariffs on pharmaceutical imports by the U.S. in August 2025 posed challenges, with Indian exporters facing increased costs and competitive disadvantages. (apnews.com) The subsequent withdrawal of tariffs on generic drugs in October 2025 provided some relief, yet the episode underscores the volatility of trade policies and the need for exporters to remain agile. (medboundtimes.com)

In the European Union, compliance with the Falsified Medicines Directive requires stringent serialization and traceability measures. For companies like BE, ensuring adherence to these regulations is crucial to maintain market access and uphold their reputation for quality.

Biological E. Limited — Regulatory Compliance & Quality Standards

Regulatory compliance remains a cornerstone for Indian pharmaceutical exporters. The U.S. FDA has intensified inspections, with over 200 conducted in 2023 and plans to increase this number in 2024. (fact.net.in) Instances of quality issues and FDA warnings have previously affected the reputation of Indian pharma exports. (svhealthcare.in) For BE, maintaining compliance with FDA, WHO, and EU Good Manufacturing Practices (GMP) is imperative to sustain and expand its export footprint.

The company's recent WHO pre-qualification for nOPV2 reflects its commitment to quality and regulatory excellence. However, the broader industry faces challenges related to counterfeit drugs and quality concerns, which can impact India's reputation as a reliable supplier. (fact.net.in) Proactive measures, including robust quality assurance systems and transparent governance, are essential for BE to navigate this evolving landscape.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Analysis Methodology

1.Product Matching: Heparin shipments identified using fuzzy matching on DGFT product description fields, validated against Indian Pharmacopoeia nomenclature.
2.Supplier Identification: Biological E. Limited matched across shipments using name normalization, accounting for company name formatting variations.
3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation. This removes the impact of unusually large one-off transactions that could distort company rankings.
4.Verified Records: This page is backed by 16 individual customs records matching Biological E. Limited exporting Heparin, covering 11 formulations to 2 countries via 4 buyers.

Government-Sourced Data

Official DGFT customs records

Transparent Methodology

Calculations fully disclosed above

Global Coverage

Exports to 137+ countries, 854+ buyers

Expert-Reviewed

Analyzed by pharmaceutical trade specialists

Heparin

Heparin

Biological E. Limited — Heparin Exporter Profile

Biological E. Limited — Heparin Export Profile: Buyers & Destinations

Where Does Biological E. Limited Export Heparin?

Who Are the Top Buyers of Heparin from Biological E. Limited?

What Is India's Total Heparin Export Value and How Much Does Biological E. Limited Contribute?

What Is the Average Shipment Value for Biological E. Limited's Heparin Exports?

How Does Biological E. Limited Compare to Other Indian Heparin Exporters?

What Heparin Formulations Does Biological E. Limited Export?

Regulatory Requirements: Exporting Heparin to Key Markets

United States — FDA

Canada — HC

How Does Biological E. Limited Compare to Nearest Heparin Exporters?

Which Indian Ports Ship Heparin Exports?

What Other Cardiovascular Products Does Biological E. Limited Export?

Geopolitical & Trade Policy Impact on Biological E. Limited's Heparin Exports

Biological E. Limited — Regulatory Compliance & Quality Standards

About Biological E. Limited

Market Intelligence

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

Analysis Methodology

Get Heparin Export Data from Biological E. Limited

Heparin Stats

Company Overview

Top Products by Biological E. Limited

Related Analysis

Need Detailed Export Data?

Data Source

BE PHARMACEUTICALS INC	UNITED STATES	$400.0K	8
BE PHARMACEUTICALS INC.	UNITED STATES	$172.1K	4
STERIMAX INC	CANADA	$150.0K	3
ATTN-GISELLE PINTO	CANADA	$0	1